adalimumab   Click here for help

GtoPdb Ligand ID: 4860

Synonyms: D2E7 [6] | Humira®
Approved drug Immunopharmacology Ligand
adalimumab is an approved drug (FDA (2002), EMA (2003))
Compound class: Antibody
Comment: Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [6]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively).

NameTrade nameCompanyClinical PhaseIndicationsReferences
adalimumab-atto; ABP 501 Amjevita; AmgevitaAmgenApproved (2016 FDA, 2017 EMA)As per reference agent[8]
adalimumab-adbm; BI 695501CyltezoBoehringer IngelheimApproved (2017 FDA and EMA)As per reference agent 
ZRC-3197ExemptiaCadila HealthcareApproved (2015 India)Rheumatoid arthritis[2,4]
adalimumab-bwwd; SB5HadlimaSamsung BioepisApproved (2019 FDA)As per originator reference agent 
adalimumab-aacf: MSB11022Idacio; KromeyaFresenius KabiApproved (2019 EMA, 2022 FDA)As per originator reference agent
BCD-057 BiocadPh 3 (NCT02762955)Plaque psoriasis 
adalimumab-adaz; GP2017Hyrimoz; Hefiya; HalimatozSandozApproved (2018 EMA and FDA)As per originator reference agent [7]
M923 Momenta PharmaceuticalsPh 3 (NCT02581345)Plaque psoriasis, rheumatoid arthritis  
adalimumab-fkjp; MYL-1401A; FKB327HulioMylan, Fujifilm Kyowa Kirin BiologicsApproved (2018 EMA, 2020 FDA)As per originator reference agent[9,12]
adalimumab-afzb; PF-06410293Abrilada; AmsparityPfizerApproved (2019 FDA, 2020 EMA)As per originator reference agent
adalimumab-aaty; CT-P17YuflymaCelltrion Healthcare Hungary KftApproved (2021 EMA, 2023 FDA)As per originator reference agent
adalimumab-aqvh; CHS-1420Yusimry Coherus BioSciencesApproved (2021 FDA)As per originator reference agent
IBI303 Innovent BiologicsPh 3 (NCT02893254)Active ankylosing spondylitis[1]
adalimumab-ryvk; AVT02Hukyndra; Libmyris; SimlandiAlvotech/DKSH/Stada Arzneimittel/TevaApproved (2021 EMA; 2024 FDA)As per originator reference agent. FDA approved this as an interchangeable biosimilar to Humira.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: adalimumab

Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
tumour necrosis factor shed form Primary target of this compound Hs Antibody Binding 8.0 pKd - 11
pKd 8.0 (Kd 1x10-8 M) [11]